Kyverna Therapeutics’ $319 Million Upsized IPO

Paul Hastings advised Kyverna Therapeutics in connection with the company’s upsized initial public offering.Kyverna Therapeutics, Inc., a patient-centered clinical-stage biopharmaceutical company focused on developing cell therapies…

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here
Sonia Carcano

Author: Sonia Carcano

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here